Vessels encapsulating tumor clusters (VETC) represent a unique tumor vascular pattern in hepatocellular carcinoma (HCC) and are closely associated with high recurrence rates and poor survival outcomes. In recent years, significant progress has been made in research on VETC in the diagnosis and treatment of HCC; however, there remains a lack of unified clinical application standards internationally. In 2026, the Third Affiliated Hospital of Naval Medical University, in collaboration with multidisciplinary experts in imaging, hepatobiliary surgery, interventional medicine, oncology, and pathology from multiple domestic hospitals, formulated the Chinese expert consensus on clinical application of vessels encapsulating tumor clusters in the diagnosis and treatment of hepatocellular carcinoma (2026 edition) based on evidence-based medicine. This consensus provides systematic specifications for the pathological diagnosis, specimen sampling, imaging evaluation, and treatment decision-making of VETC. This article systematically interprets the core contents of the consensus in light of relevant research progress both domestically and internationally.

Breast cancer is a prevalent malignant tumor in females, and 5%-10% cases are related to hereditary susceptibility. At present, domestic genetic counseling for breast cancer still has shortcomings in standardized procedures, genetic testing, multidisciplinary collaboration and individualized intervention. Based on updated global and domestic evidences and Chinese population epidemiological features, this consensus, formulated by the Committee for Integrative Prevention and Screening of Breast Cancer, China Anti-Cancer Association, adopts the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system for evidence grading. Centered on full-cycle management of hereditary breast cancer, it specifies standardized workflow of genetic counseling from the perspectives of risk assessment, genetic testing, precise treatment, preventive intervention, long-term follow-up, fertility guidance, and ethical norms and constructs a closed-loop management system of “testing-interpretation-intervention-follow up”, in order to guide clinical practice for medical staff, patients, high-risk relatives and public health administrators.

翼状胬肉是常见眼表疾病，手术切除是其主要治疗方式之一。术后复发及相关并发症可导致非计划再次手术，影响患者视觉质量和眼表舒适度，并增加结膜组织损耗、瘢痕形成及再次手术难度。非计划再次手术率是反映手术质量安全的重要结果指标。为统一翼状胬肉术后非计划再次手术率的指标定义、统计口径、数据来源、病例核查和质量改进路径，本共识建议将"术后1年内"作为主要观察时间窗，以患眼为统计单位，以同一患眼术后365 d内因翼状胬肉复发或首次手术相关并发症发生的非计划再次手术例次数作为分子，以同期已满1年观察期的翼状胬肉首次手术患眼总数作为分母。国际疾病分类(ICD-10)编码"翼状胬肉(H11.0)"可以作为疑似病例筛查入口，但不能直接替代最终分子判定。最终纳入应经手术编码匹配、时间窗限定、患眼核查和病案证据链确认。本共识旨在为翼状胬肉术后非计划再次手术率的规范统计、质量评价及持续改进提供统一依据。

Hyperandrogenism (HA) is a pathological condition in which circulating androgen levels are abnormally elevated in women. It commonly presents with acne, hirsutism, oligomenorrhea, or amenorrhea, and may impair reproductive capacity. In June 2025, Society for Endocrinology released the latest Clinical Practice Guideline for the Evaluation of Androgen Excess in Women (hereafter referred to as " the Guideline" ), providing evidence-based recommendations for the evaluation and management of HA in women. The Guideline was initiated by integrating professional knowledge from endocrinology, obstetrics and gynecology, clinical biochemistry, and nursing, offering clinicians a unique perspective on patients with HA. The Guideline based on evidence-based medicine, provides multiple disciplinary team (MDT) diagnostic and therapeutic guidance for the clinical assessment, hormone testing, gonadotropin-releasing hormone (GnRH) suppression test, 96-hour dexamethasone suppression test (DST) and imaging examinations in women with HA. Based on the Guideline, the authors intend to focus on the androgen metabolic pathways and regulatory mechanisms in women, the disease spectrum and clinical features of women with HA, as well as the differential diagnosis from other diseases and the clinical evaluation system: interpreting the entire process from medical history to imaging examinations in women with HA, with the aim of providing a reference for the standardized diagnosis and treatment of women with HA in clinical practice.

Pancreatic allograft resection serves as a critical surgical intervention for severe complications arising from pancreatic allograft dysfunction, directly influencing recipient outcomes. Currently, no expert consensus or guidelines are available domestically and internationally to standardize its clinical application. This consensus systematically delineates the indications, timing, key technical aspects, perioperative management, and psychological assessment and intervention strategies for pancreatic allograft resection. Indications are classified by time of onset into early (thrombosis, transplant pancreatitis), intermediate (intra-abdominal infection, invasive vasculitis), and late stage (rejection, vascular complications, and de novo tumor), with a clear recommendation for conservative management in asymptomatic allograft dysfunction. Surgical techniques should be tailored to the original transplant procedure (including systemic/portal venous drainage and enteric/bladder drainage methods), focusing on vascular control, thrombosis management, and reconstruction of digestive/urinary anastomoses. Postoperative management involves management of complications, blood glucose regulation, adjustment of immunosuppressive regimens, and systematic psychosocial interventions, underscored by multidisciplinary collaboration to optimize patient outcomes. This consensus aims to establish a standardized reference for clinical practice, ultimately improving long-term quality of life for recipients.